Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 63 clinical trials
The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin Comparing With Standardized Statin

efficacy and safety of combined therapy with red yeast rice and low-dose atorvastatin in persons with mild atherosclerotic cardiovascular disease and who qualified for statin therapy according to national

low density lipoprotein
cardiovascular disease
statin therapy
LDL Cholesterol
  • 02 Feb, 2021
  • 1 location
Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI

meeting the exclusion criteria will be included in the study. Initially, lipid-lowering treatment with atorvastatin is prescribed at a dose of 80 mg / day from the first 24-96 hours of AMI in

  • 24 Jan, 2021
  • 1 location
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

- atorvastatin. All three have been known for a long time and have been shown to be effective against other viruses. In addition, they are generic, inexpensive and readily available in all countries. The

  • 12 Feb, 2021
  • 2 locations
Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

The purpose of this study is to evaluate whether statin could prevent recurrence of hepatocellular carcinoma after curative treatment

  • 25 Jan, 2021
  • 8 locations
Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study

Anthracycline (AC) chemotherapy has substantially reduced the mortality rate from several common cancers globally. Unfortunately, AC treatment is associated with up to 19% risk of heart failure (HF). Current standard of care for preventing AC induced HF (AIHF) is cardiac surveillance followed by initiation of treatment once HF is diagnosed. …

heart failure
myocardial dysfunction
  • 24 Jan, 2021
  • 1 location
Investigation of the Gut Microbiome and Statin Response

There is evidence that the bacteria that naturally reside in the gut can influence how well we respond to medications. Therefore this study will look at how rosuvastatin, a medication used to lower cholesterol levels, may change the bacteria in the gut. Investigators will also examine how the gut bacteria …

  • 27 Jan, 2021
  • 1 location
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)

Atherosclerosis in the setting of HIV infection is distinct and includes increased vascular inflammation, worsened endothelial function, and a predominance of non-calcified plaque. These outcomes can be assessed using specialized noninvasive imaging which strongly predict future CV events in the general population. PCSK9 has emerged as an important pharmacologic target …

peripheral artery disease
statin therapy
myocardial infarction
  • 24 Jan, 2021
  • 1 location
STAT-STatin and Aspirin in Trauma

This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with fibrinolysis shutdown.

venous thromboembolism
  • 24 Jan, 2021
  • 1 location
Post Implantation Syndrome and Administration on NSAIDs in Patients Undergoing EVAR for AAA

INTRODUCTION Post-implantation syndrome is the clinical and biochemical expression of an inflammatory response following endovascular repair of an aortic aneurysm. PIS is mainly a clinical condition associated with the implantation of an endograft and is diagnosed by the presence of fever accompanied by elevated WBC count above normal without any …

aortic aneurysm
  • 22 Jan, 2021
  • 1 location
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC

Lung cancer is the most common cancer, accounting for 20% of cancer-related deaths worldwide. In 2015, an estimated 610,200 patients (22 per cent of cancer-related deaths) died of lung cancer. Non-small cell lung cancer ((NSCLC)) accounts for 80% to 85% of lung cancer. Most patients are locally advanced or metastatic …

  • 23 Jan, 2021
  • 1 location